By Daniella Parra
Promontory Therapeutics said its Phase 2 meeting with the FDA cleared the way to launch a Phase 3 registrational trial of PT-112 monotherapy for metastatic castration-resistant prostate cancer.
The company is a small, NYC-based biotech that, to date, has only been funded by family offices, they said.
Company data reported that PT-112 induced robust immune activation and immunogenic cell death across the adaptive and innate immune systems, playing a significant role in its anti-cancer mechanism.
Contact:
